LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) announced it has been added to the Russell Microcap(R) Index, effective after the close of U.S. markets on June 26, 2026, with the reconstituted index taking effect at the opening of trading on June 29, 2026. The company stated that inclusion in the widely followed benchmark is expected to increase its visibility among institutional investors and investment products that track Russell indexes.
LIXTE said the milestone reflects progress under its new leadership and strategic direction and supports its efforts to build a platform focused on AI energy infrastructure equipment and services. The Russell Microcap Index is reconstituted annually and measures the performance of smaller publicly traded U.S. companies.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that LB-100, its lead compound and first-in-class clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
For the full press release, visit https://ibn.fm/r6l81.
